| Date |
Subject |
Media |
| 2025-08-12 |
UnicoCell Biomed Advances Main Board Listing Plans, Focusing on Irreversible Diseases in Regenerative Medicine
|
UnicoCell Biomed, a key player in the field of regenerative medicine, has officially launched its plan to transfer its listing to Taiwan’s main board. The company is currently focused on regenerative treatments for irreversible diseases. Among its core pipelines, the chronic kidney disease (CKD) therapy is expected to file for a Phase III clinical trial in Taiwan next year, while overseas licensing discussions are also underway. In addition, patient enrollment for its Phase III clinical trial targeting knee osteoarthritis is anticipated to be completed by the end of this year. Meanwhile, UnicoCell is expanding the scientific data surrounding its exosome technology for both aesthetic and therapeutic applications, broadening the scope of its raw material offerings. |
| 2025-08-12 |
New Power Joins Taiwan’s Vaccine National Team: NHRI Spin-Off "TaiU Biotech" Secures NT$60 Million in Seed Funding Led by Mosaic Seed Fund
|
A new force has joined Taiwan’s vaccine national team. TaiU Biotech, a startup spun off from the National Health Research Institutes (NHRI), announced yesterday (July 31) that it has successfully closed a NT$60 million seed funding round with support from Mosaic Venture Lab. The round was led by the Mosaic Seed Fund, and with assistance from the Small and Medium Enterprise and Startup Administration of the Ministry of Economic Affairs and the National Innovation and Entrepreneurship Association, TaiU also secured co-investment from the National Development Fund. |
| 2025-08-12 |
BIONET Therapeutics’ UCMSC Exosome Drug Substance Receives FDA DMF Type II Registration Approval
|
BIONET Therapeutics, a subsidiary of BIONET Corp., announced that it has received notification from the U.S. Food and Drug Administration (FDA) approving the Drug Master File (DMF) Type II registration for its proprietary umbilical cord mesenchymal stem cell (UCMSC) exosome drug substance. |
| 2025-08-12 |
Foresee Pharmaceuticals Files for CAMCEVI Launch in Singapore
|
Foresee Pharmaceuticals announced that its licensing partner, Changchun GeneScience Pharmaceutical, has submitted a marketing application to Singapore’s Health Sciences Authority (HSA) for CAMCEVI 42mg, a new formulation developed for the treatment of prostate cancer. |
| 2025-08-12 |
KMUH Achieves HIMSS EMRAM Stage 7 Certification
|
In response to the digital wave driven by big data and artificial intelligence (AI), Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) has achieved Stage 7 of the Electronic Medical Record Adoption Model (EMRAM) certification by the Healthcare Information and Management Systems Society (HIMSS)—the highest international recognition in medical information management systems. KMUH is the first medical institution in southern Taiwan to receive this prestigious honor. |
| 2025-08-12 |
Biomedica Corporation Secures Thai Medical Certification in Just Eight Months—Reveals Three Core Strategies for Market Entry
|
Biomedica Corporation, which has actively expanded into international markets in recent years, has achieved notable success in Thailand. During the “New Southbound Healthcare Market Expansion Experience Sharing Session,” Biomedica’s Founder and Chief Marketing Officer, Ming-Hsiang Lin, shared how the company successfully obtained TFDA (Thai Food and Drug Administration) certification in just eight months. He also revealed for the first time the company’s three core strategies for entering the Thai market—offering valuable insights for medical startups targeting Southeast Asia. |
| 2025-08-12 |
Blueprint for a Super-Aged Future City: Experts Share Insights at the “Age-Friendly Cities Forum”
|
“I came to confess on July 30—our urban planning has fallen behind, because we had no prior experience with such longevity!” joked LIN, CHIEN YUAN, Professor at the Graduate Institute of Building and Planning, National Taiwan University. His comment, though made with a touch of humor, rang a serious alarm: it’s time for everyone to address the realities of a super-aged society. |
| 2025-08-12 |
Bora Pharmaceuticals’ Q2 Gross Margin Expected to Outperform Q1; Dual Growth Engines to Boost Second-Half Performance
|
Bora Pharmaceuticals reported second-quarter revenue of NT$5.18 billion, slightly below market expectations, mainly due to the appreciation of the New Taiwan dollar and production delays at its sterile injectable plant in Maryland, USA. With the shutdown impact from the first quarter now resolved, the company’s Q2 gross margin is expected to surpass that of Q1. Looking ahead to the second half of the year, the market expansion of the pediatric epilepsy oral solution VIGAFYDE and increasing CDMO orders—totaling US$138 million in new orders during the first half—are anticipated to steadily boost performance. Analysts are optimistic that these dual engines will drive a significant rebound in gross and operating margins in the latter half of the year. |
| 2025-08-12 |
Orient Europharma Group Maintains Steady Growth, Eyes Drug License Acquisitions and M&A in Southeast Asia to Accelerate Expansion
|
Orient Europharma Group is advancing its dual-track strategy, and General Manager Calvin Tsai stated that the company will continue launching new products to expand its reach across all age demographics while actively expanding into Southeast Asian markets. In the future, the company plans to partner with Orient Pharma to enter markets such as the United States and even the Middle East. This year’s revenue is expected to achieve single-digit growth. With ample cash from asset disposals, the company will continue seeking suitable targets to enrich its product portfolio. In addition to equity-based partnerships, it does not rule out acquiring drug licenses or companies to accelerate its Southeast Asia expansion. |
| 2025-08-12 |
ACRO Biomedical Signs Licensing Agreement with Vietnam’s CT Group to Market Regenerative Eye Implant Across ASEAN
|
ACRO Biomedical has officially signed a licensing agreement with Vietnam’s CT Group to market its regenerative corneal implant—the “Apis Cor Collagen Corneal Matrix”—across ASEAN countries. The product has already received medical device certification from Taiwan’s Ministry of Health and Welfare and has been gaining momentum internationally. Following a prior agreement with Australia’s Oculus Biomed Pty Ltd (OBM) to conduct clinical trials, obtain regulatory approval, and commercialize the product, this new partnership with CT Group not only boosts ACRO Biomedical’s revenue but also showcases Taiwan’s regenerative medicine capabilities while offering new hope to patients in Southeast Asia. |
